Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  temozolomide
Find trials that include:  Any drugs shown
Results 1-25 of 66 for your search:
Start Over
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-498, NCI-2016-00144, 2015-003739-37, NCT02617589
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 021-003, NCI-2010-01643, NCT00394628
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
Methoxyamine and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9483, NCI-2013-00877, 130118, P121184, 13-C-0118, NCT01851369
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Talazoparib and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-251, NCI-2017-00326, BBI608-201GBM, NCT02315534
Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-121, NCI-2015-01724, NCT02446704
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients with Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0899, NCI-2016-00183, NCT02661282
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BMX-HGG-001, NCI-2016-00288, NCT02655601
Disulfiram and Copper Gluconate with Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma That Can Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201604115, NCI-2016-00623, NCT02715609
Temozolomide with or without TG02 in Treating Patients with Recurrent Anaplastic Astrocytoma, Glioblastoma, or Gliosarcoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0009, NCI-2016-01621, NCT02942264
Trastuzumab Emtansine with or without Temozolomide in Preventing Development of Brain Metastases after Stereotactic Radiosurgery in Patients with HER2 Positive Brea t Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0115, NCI-2017-01113, NCT03190967
Temozolomide and Lapatinib Ditosylate in Treating Patients with Recurrent Low-Grade Ependymoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-N005, NCI-2012-02131, CERN 08-02, P152451, NCT00826241
Ondansetron with or without Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Gliomas
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00031206, NCI-2013-00520, NCT01450826
Low-Dose Fractionated Radiation Therapy and Temozolomide in Treating Patients with Recurrent Anaplastic Astrocytoma or Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J11120, NCI-2012-02048, CIR00006742, NA_00065863, NCT01466686
Lapatinib Ditosylate, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LAP115352, NCI-2012-00779, 12-000493, NCT01591577
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Dinutuximab in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01, NCT01767194
Low-Dose Whole-Brain Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GCC 1224, NCI-2014-00773, 1224GCC, HP-00053043, NCT01822275
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, NCT01827384
Start Over